Clinical Trial Update: A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy [Phase 3]

View source ↗

Summary

Phase 3 study of mavacamten for non-obstructive hypertrophic cardiomyopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy
• Non-obstructive Hypertrophic Cardiomyopathy

Drugs mentioned

• CAMZYOS (MAVACAMTEN)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Cardiomyopathy, Hypertrophic | Phase 3 | Status: COMPLETED